• Plurilock Security (PLUR) has closed the second tranche of its non-brokered private placement financing
  • In addition, the company has increased the offering from $1,500,000 to $2,500,000
  • Net proceeds will be used for general corporate purposes
  • Plurilock provides identity-centric cybersecurity for today’s workforce
  • Plurilock Security Inc. opened trading at $0.125

Plurilock Security (PLUR) has closed the second tranche of its non-brokered private placement financing.

In addition, the company has increased the offering from $1,500,000 to $2,500,000.

The second tranche consisted of 2,447,022 units of the company at a price of $0.14 per unit, for aggregate gross proceeds of $342,583.08, bringing the aggregate gross proceeds of the offering to $1,556,120.30.

Each unit consists of one common share in the capital of the company and one common share purchase warrant.

Each warrant entitles the holder to acquire one additional share at a price of $0.25 per warrant share until December 30, 2024.

The second tranche was completed in line with the listed issuer financing exemption under Part 5A of National Instrument 45-106 Prospectus Exemptions. Therefore the securities issued in the offering are not subject to a hold period in accordance with applicable Canadian securities laws.

Plurilock plans to use the proceeds raised from the offering for general corporate purposes.

The company expects to close one or more additional tranches of the offering.

Plurilock provides identity-centric cybersecurity for today’s workforces. The Plurilock family of companies enables organizations to operate safely and securely while reducing cybersecurity friction.

Plurilock Security Inc. opened trading at $0.125.


More From The Market Online

Westinghouse Electric files for US IPO

Westinghouse Electric Company, jointly owned by Cameco and Brookfield Renewable Partners, confidentially filed for a US IPO.

Buzz on the Bullboards: Contracts, cashflows, and delistings

Uncertainty around Iran has weighed on sentiment, reminding investors that even strong stories can be overshadowed by geopolitical risk.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.